SeqLL Installs true Single Molecule Sequencing (tSMS®) Instrument to Support Oncology Research by Dr. David Ting, MD at the ...
November 03 2017 - 10:45AM
Business Wire
SeqLL, LLC announced today that it has installed a true Single
Molecule Sequencing (tSMS) Instrument at the Harvard-MGH Cancer
Center to support oncology research conducted by Dr. David Ting,
MD. Dr. Ting is Assistant Professor of Medicine at Harvard Medical
School and a medical oncologist with a focus on gastrointestinal
malignancies. The Ting laboratory utilizes RNA-sequencing and RNA
in situ hybridization technologies to understand the complex
transcriptional landscape of cancers. The laboratory has used these
technologies to identify non-coding RNA (ncRNA) sequences that are
differentially expressed in cancer versus normal tissues. This work
led to the identification of repeat ncRNAs that were aberrantly
expressed across all major epithelial cancers and has opened the
door to a new area of research that has the opportunity to identify
novel biomarkers and therapeutic targets.
Accurate and reproducible RNA transcriptome analysis has
traditionally been challenging for Next Generation Sequencing (NGS)
platforms due to errors associated with reverse transcription,
amplification and manipulations during library preparation. The
detection of low fold changes and identification of rare
transcripts remains difficult on these platforms, particularly when
using FFPE and other degraded or low input sample types. SeqLL tSMS
technology sequences individual strands of first strand cDNA or RNA
directly, without amplification or library prep, providing accurate
RNA sequence information that reflects the true information content
of each sample without introduced bias or sample loss.
“SeqLL is extremely pleased that Dr. Ting has
chosen the tSMS platform to continue his research into pancreatic
cancer. David is conducting groundbreaking research and SeqLL is
excited to be able to provide the level of accuracy,
reproducibility and unbiased molecule counting capabilities
necessary for this work,” said Dr. Elizabeth E. Reczek, CEO of
SeqLL.
About SeqLL and tSMSLocated in Woburn, MA, SeqLL, LLC was
founded in 2013 to bring a range of discovery and development
services, based on the company’s proprietary true Single Molecule
Sequencing (tSMS) platform, to the research and healthcare
communities. tSMS enables direct parallel sequencing of millions of
individual molecules. Sample composition is precisely determined
without bias or loss of diversity via a simple, integrated
workflow. tSMS can deliver linear quantification over a 5-log range
and sensitivity to 1.2-1.5-fold differences in expression levels.
It is ideal for fragment sizes as low as 25 base pairs and can
yield valuable data from even picogram-level input.
About David Ting, MDAssistant Professor of Medicine,
Department of Medicine, Harvard Medical School, Cambridge,
MAPrincipal Investigator, Massachusetts General Hospital Cancer
Center, Charlestown, MAAssistant Physician, Hematology/Oncology,
Massachusetts General Hospital Cancer Center, Boston, MA
Dr. Ting is Assistant Professor of Medicine at Harvard Medical
School and a medical oncologist with a focus on gastrointestinal
malignancies at the Massachusetts General Hospital (MGH) Cancer
Center. After receiving undergraduate degrees in chemical
engineering and biology from M.I.T., he completed his medical
degree at Harvard Medical School. He completed internal medicine
residency at the MGH and medical oncology fellowship in the
combined Dana Farber Cancer Institute and MGH Cancer Center
program. During his undergraduate and medical training, Dr. Ting
trained with Robert Langer in the MIT Chemical Engineering
Department working on nucleic acid delivery vehicles and George
Daley at the Whitehead Institute on stem cell biology. He performed
his post-doctoral training with Daniel Haber at the MGH Cancer
Center, where he began work characterizing circulating tumor cells
(CTCs) and primary tumors with RNA-sequencing.
For more information, please visit www.SeqLL.com.
All products are for research use only and are
not intended for diagnostic uses.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171103005548/en/
SeqLL, LLCElizabeth ReczekCEOmedia@seqll.com